Hot Pursuit     28-Jul-22
Biocon Q1 PAT climbs 71% YoY to Rs 144 cr
The biotech company's consolidated net profit surged 71.1% to Rs 144.40 crore on 21.5% jump in revenue from operations to Rs 2,139.50 crore in Q1 FY23 over Q1 FY22.

Total revenue grew 22.7% to Rs 2,217.40 crore in Q1 FY23 as against Rs 1,807.80 crore posted in Q1 FY22. Profit before tax stood at Rs 196.90 crore in Q1 FY23, up 18.8% from Rs 165.70 crore recorded in the corresponding quarter previous year.

Consolidated EBITDA rose 9% to Rs 478 crore in Q1 FY23 as compared to Rs 437 crore reported in Q1 FY22. EBITDA margin decreased to 22% in Q1 FY23 as against 24% recorded in the same period last year. Core EBITDA jumped 25% to Rs 660 crore in the first quarter from Rs 530 crore posted in Q1 FY22.

Net profit margins increased to 7% in Q1 FY23 as compared to 5% in Q1 FY22. Gross research & development (R&D) spend soared 64% to Rs 223 crore in Q1 FY22 as against Rs 136 crore posted in the same period a year ago.

Revenue from Generics was Rs 580 crore (up 19% YoY), Biosimilars revenue stood at Rs 977 crore (up 29% YoY) and revenue from Research services was Rs 645 crore (up 8% YoY).

Kiran Mazumdar-Shaw, executive chairperson of Biocon and Biocon Biologics, said, "We have had a strong start to the year. At a consolidated level, YoY revenues grew 23% backed by robust growth in both Biosimilars (29%) and Generics (19%). Core EBITDA grew 25% and margin improved to 31% compared to 30% in Q1FY22 and Net Profit grew 71% to Rs 144 crore. Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains. R&D investments increased significantly by Rs 87 crore this quarter reflecting pipeline progression to deliver future growth. All our three businesses are poised for the next phase of strong and sustainable growth which has been challenged during the two years of the COVID-19 pandemic."

Biocon is a global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer, and autoimmune.

Shares of Biocon were down 4.66% to Rs 307.75 on the BSE.

Previous News
 ( Results - Analysis 17-May-24   10:41 )
  Biocon reports consolidated net profit of Rs 660.00 crore in the December 2023 quarter
 ( Results - Announcements 09-Feb-24   07:41 )
  Biocon Ltd spurts 1.22%, gains for third straight session
 ( Hot Pursuit - 07-Jun-24   13:05 )
  Biocon CFO resigns
 ( Corporate News - 08-Feb-24   19:43 )
  Biocon Biologics completes integration of Viatris' biosimilars business in 31 European countries
 ( Corporate News - 30-Nov-23   16:49 )
  Biocon receives reaffirmation in credit rating for bank facilities
 ( Corporate News - 30-Nov-23   15:49 )
  Biocon Biologics update on USFDA's CRL issued to partner Viatris (Mylan)
 ( Corporate News - 13-Feb-23   09:20 )
  Biocon says USFDA issues CRL for biologics license application for Bevacizumab
 ( Hot Pursuit - 13-Feb-23   08:32 )
  Biocon signs exclusive licensing and supply agreement with Handok
 ( Corporate News - 24-May-24   09:06 )
  Biocon gains after subsidiary secures 'Yesafili' entry into Canadian market
 ( Hot Pursuit - 04-Mar-24   11:42 )
  Biocon announces resignation of senior management
 ( Corporate News - 08-Feb-24   19:49 )
Other Stories
  Bondada Engg board grants nod to 1:5 stock-split
  16-Jul-24   16:52
  Pearl Global spurts after HDFC MF buys stake
  16-Jul-24   16:00
  Bharti Hexacom soars after broker initiates coverage
  16-Jul-24   15:34
  Ujaas Energy hits record high as board OKs 1:4 bonus issue
  16-Jul-24   15:34
  Century Textiles Q1 PAT drops 47% YoY to Rs 28 cr
  16-Jul-24   15:34
  Himadri Specialty spurts after Q1 PAT climbs 42% YoY
  16-Jul-24   15:19
  Jupiter Wagons Ltd leads losers in 'A' group
  16-Jul-24   15:00
  Sheetal Cool Products Ltd leads losers in 'B' group
  16-Jul-24   14:45
  Bajaj Auto gains after Q1 PAT jumps 19% YoY To Rs 1,988 cr
  16-Jul-24   14:41
  Volumes soar at Alembic Pharmaceuticals Ltd counter
  16-Jul-24   14:30
Back Top